SI1511496T1 - Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo - Google Patents

Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo

Info

Publication number
SI1511496T1
SI1511496T1 SI200330587T SI200330587T SI1511496T1 SI 1511496 T1 SI1511496 T1 SI 1511496T1 SI 200330587 T SI200330587 T SI 200330587T SI 200330587 T SI200330587 T SI 200330587T SI 1511496 T1 SI1511496 T1 SI 1511496T1
Authority
SI
Slovenia
Prior art keywords
treating
pharmaceutical formulation
aforementioned
immune mediated
estrogenic component
Prior art date
Application number
SI200330587T
Other languages
English (en)
Inventor
Evert Johannes Bunschoten
Bennink Herman Jan Ti Coelingh
Christian Franz Holinka
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Publication of SI1511496T1 publication Critical patent/SI1511496T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200330587T 2002-06-11 2003-06-11 Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo SI1511496T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077272 2002-06-11
PCT/NL2003/000422 WO2003103684A1 (en) 2002-06-11 2003-06-11 Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein

Publications (1)

Publication Number Publication Date
SI1511496T1 true SI1511496T1 (sl) 2007-04-30

Family

ID=29724474

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200330587T SI1511496T1 (sl) 2002-06-11 2003-06-11 Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo

Country Status (13)

Country Link
US (1) US7923440B2 (sl)
EP (1) EP1511496B1 (sl)
CN (1) CN1691947B (sl)
AT (1) ATE340579T1 (sl)
AU (1) AU2003274946A1 (sl)
CA (1) CA2489271C (sl)
CY (1) CY1105883T1 (sl)
DE (1) DE60308679T2 (sl)
DK (1) DK1511496T3 (sl)
ES (1) ES2274252T3 (sl)
PT (1) PT1511496E (sl)
SI (1) SI1511496T1 (sl)
WO (1) WO2003103684A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342537B (es) 2011-06-01 2016-10-04 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
MX341561B (es) 2011-06-01 2016-08-25 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
CA2924255C (en) 2013-09-18 2022-11-22 Crystal Pharma, S.A.U. Process for the preparation of estetrol
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
NO3106148T3 (sl) 2015-06-18 2018-08-11
WO2016203009A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
KR101996390B1 (ko) * 2017-04-21 2019-07-04 이화여자대학교 산학협력단 아미노퀴놀린계 화합물을 포함하는 면역 증강용 조성물, 조절 t 세포로의 분화 촉진용 조성물, 및 이를 이용한 방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2336434A1 (de) 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336433A1 (de) 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) * 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
ES2247710T3 (es) 1997-06-20 2006-03-01 Akzo Nobel N.V. Antagonista de gonadotropina.
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
JP2003527310A (ja) 1999-04-16 2003-09-16 イエナフアルム ゲーエムベーハー ウント ツェーオー． カーゲー エストロゲンを局部的に皮内投与するための医薬品組成物または化粧品組成物
US7273932B1 (en) 1999-05-28 2007-09-25 The University Of Cincinnati Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
EP1286664B1 (en) 2000-05-12 2007-07-25 Oregon Health and Science University Combination of low dose estrogen and immunotherapeutic agent for treating immune diseases
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy

Also Published As

Publication number Publication date
CA2489271A1 (en) 2003-12-18
PT1511496E (pt) 2007-01-31
US7923440B2 (en) 2011-04-12
ES2274252T3 (es) 2007-05-16
DK1511496T3 (da) 2007-02-05
CN1691947A (zh) 2005-11-02
WO2003103684A1 (en) 2003-12-18
AU2003274946A1 (en) 2003-12-22
DE60308679T2 (de) 2007-08-16
CN1691947B (zh) 2011-11-23
EP1511496A1 (en) 2005-03-09
CY1105883T1 (el) 2011-02-02
US20050261209A1 (en) 2005-11-24
EP1511496B1 (en) 2006-09-27
ATE340579T1 (de) 2006-10-15
DE60308679D1 (de) 2006-11-09
CA2489271C (en) 2011-12-06

Similar Documents

Publication Publication Date Title
DK1446128T3 (da) Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
DK1390040T3 (da) Farmaceutisk præparat til anvendelse i hormonerstatningsterapi
SI1511496T1 (sl) Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
WO2002094275A8 (en) Use of estrogen compounds to increase libido in women
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
HK1095138A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
TW200728289A (en) Non-basic melanin concentrating hormone receptor-1 antagonists
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
LU91079I2 (fr) Tramacet et ses dérivés pharmaceutiquement acceptables.
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
PL2170346T3 (pl) Leczenie lub profilaktyka zaburzeń związanych z nadciśnieniem w okresie ciąży lub opóźnienie wzrostu płodu
MXPA02001571A (es) Metodo de tratamiento para el cancer.
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
PT1583538E (pt) Utilização da 3-metoxi-pregnenolona para a preparação de um medicamento destinado a tratar as doenças neurodegenerativas
IL147149A0 (en) Novel diphenyl-piperidine derivate
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
WO2001089499A3 (en) Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
HUP0300585A2 (hu) Eljárás azalidet tartalmazó antibiotikum-készítmények alkalmazására emlősök bakteriális és protozoa fertőzésének kezelésére vagy megelőzésére
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
BRPI0412118A (pt) métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
HUP0303610A2 (hu) Jóindulatú prosztatatúltengéssel összefüggő húgyhólyag-irritációs tünetek kezelésére alkalmas készítmény